16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE

US Bancorp DE bought a new position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,178 shares of the company’s stock, valued at approximately $31,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its position in shares of Mersana Therapeutics by 976.7% during the 1st quarter. Russell Investments Group Ltd. now owns 9,453 shares of the company’s stock valued at $42,000 after acquiring an additional 8,575 shares during the last quarter. Algert Global LLC purchased a new stake in shares of Mersana Therapeutics during the second quarter valued at $90,000. Walleye Trading LLC acquired a new position in shares of Mersana Therapeutics in the 1st quarter valued at $141,000. Exchange Traded Concepts LLC increased its stake in Mersana Therapeutics by 95.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 85,006 shares of the company’s stock worth $161,000 after purchasing an additional 41,586 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in Mersana Therapeutics by 262.1% during the 2nd quarter. XTX Topco Ltd now owns 121,432 shares of the company’s stock worth $244,000 after buying an additional 87,893 shares during the period. Institutional investors and hedge funds own 93.92% of the company’s stock.

Insider Activity

In other news, CEO Martin H. Jr. Huber sold 50,423 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $1.76, for a total transaction of $88,744.48. Following the transaction, the chief executive officer now owns 116,327 shares in the company, valued at approximately $204,735.52. This trade represents a 30.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 70,849 shares of company stock worth $129,184 in the last three months. 11.80% of the stock is owned by insiders.

Mersana Therapeutics Stock Down 4.5 %

MRSN stock opened at $2.11 on Tuesday. The company has a 50 day moving average of $2.05 and a two-hundred day moving average of $2.04. The company has a quick ratio of 2.72, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics, Inc. has a 12-month low of $1.22 and a 12-month high of $6.28. The company has a market cap of $260.65 million, a price-to-earnings ratio of -3.46 and a beta of 1.50.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The firm had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $7.53 million. During the same quarter last year, the firm earned ($0.35) earnings per share. The business’s revenue for the quarter was up 63.6% on a year-over-year basis. On average, equities analysts anticipate that Mersana Therapeutics, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird cut their price target on shares of Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Lifesci Capital raised shares of Mersana Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Finally, Citigroup began coverage on Mersana Therapeutics in a research report on Friday. They issued a “buy” rating and a $5.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.00.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.